COLLEGIUM PHARMACEUTICAL, INC 8-K

What Happened
On January 8, 2026, Collegium Pharmaceutical, Inc. announced full-year revenue and adjusted EBITDA guidance for 2026 via a press release and investor presentation. The company furnished the press release under Item 7.01 (Regulation FD Disclosure) in an 8-K filing dated January 8, 2026.

Key Details

• Filing date: January 8, 2026 (Form 8-K, Item 7.01 — Regulation FD Disclosure).
• Announcement format: Press release and investor presentation attached as Exhibits 99.1 and 99.2 to the 8-K.
• Subject: Full-year 2026 revenue and adjusted EBITDA guidance (specific guidance figures are included in the attached press release and presentation).
• Disclosure status: Information was furnished to the SEC (furnished, not filed).

Why It Matters
Guidance on full-year revenue and adjusted EBITDA is management’s forward-looking view of company performance and is a primary input for investor expectations, analyst models, and valuation. Investors should review the attached press release and investor presentation for the specific numerical guidance and any commentary on assumptions, which may affect short‑term stock reactions and estimates for 2026 earnings.